Market Research Logo

Conference Documentation: Cancer Vaccines

Conference Documentation: Cancer Vaccines

Cancer Vaccines are medicines that boost the immune’s natural ability to protect the body against “foreign invaders,” mainly infectious agents that may cause disease as opposed to chemotherapy and radiotherapy that utilize chemical drugs and radiation, respectively.

Increased knowledge in our immune system has opened up new combination therapies in immuno-oncology, to enhance immune response to vaccines. Thus, some new treatments include use of monoclonal antibodies and genetically engineered viral vectors to kill tumours.

Research is rapidly growing in targeted immuno-therapy, involving treatment in the form of peptide vaccines (T and B cell epitopes), DNA vaccines and vaccination using dendritic cells, viral vectors, antibodies and adoptive transfer of T cells.

However, it has also become clear that cancer cells have different ways of eluding the immune system, which makes creating effective vaccines difficult. Thus, vaccines are now often given along with other substances (called adjuvants) that help boost the body’s immune response, which might help the vaccines work better.

Researchers are also studying the best way to give vaccines, looking to see if they work better when used alone or with other types of cancer treatments.


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
9:10
OPENING ADDRESS: The Provocative Issue of Tumor Genetic Heterogeneity in Immunotherapy
Michael Hanna, CEO, Vaccinogen
9:50
Optimizing Formulation Development Strategies for Vaccine Adjuvants
Derek O'Hagan, Vaccines Formulation, Novartis Pharmaceuticals Corp
10:30
Morning Coffee
11:00
Translational Biomarkers and Diognostic Tools in Oncology
Vaios Karanikas, Biomarker Experimental Medicine Leader and Senior Principle Scientist, Roche
11:40
Round Table discussion
Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
12:20
Networking Lunch
13:30
Establishing a fully-personalised cancer treatment
Ravi Madan, Genitourinary Malignancies Branch , National Cancer Institute
14:10
Four into One does go: The use of integrated genomic, proteomic, immunological and bioinformatic platforms to identify novel immunological biomarkers of disease and predict outcomes of disease
Graham Pockely, Associate Director, Cancer Research UK
14:50
Afternoon Tea
15:20
Industry Perspective: Combination therapies to advance immune-oncology vaccines and enhance patient outcomes
Thomas Felzmann, CEO, Activartis Biotech GmbH
15:50
Understanding Tumor-Host Interactions
Dirk Jager, Head of the Medical Oncology Department National Center for Tumor Diseases, University Hospital Heidelberg
16:30
Oncolytic virotherapy: cancer immunotherapy as nature intended
Hardev Pandha, Senior Lecture in Medcial Oncology, St Georges Hospital Medical School
17:10
PANEL DISCUSSION: Where is the Future for Cancer Vaccines?
Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
17:10
PANEL DISCUSSION: Where is the Future for Cancer Vaccines?
Ravi Madan, Genitourinary Malignancies Branch , National Cancer Institute
17:40
Chairman’s Closing Remarks and Close of Day One
Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
9:10
Therapeutic Cancer Vaccines
Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
9:50
RNA- vaccinology: Building the next-generation of RNA immunogens
Sebastian Kreiter, Head Immunotherapy Development Center, TRON Translational Oncology Mainz
10:30
Morning Coffee
11:00
Developments and clinical trials in allogeneic cell-based vaccines
John Maudsley, CEO, Cancer Vaccines Ltd
11:40
Case study: Dendritic cell vaccine development for colorectal canceR
Eric Leire, CEO, DanDrit Biotech
12:20
Networking Lunch
13:30
Multi-Antigenic Chimeric Cargo Delivery Platforms
Aymen Al-Shamkhani, Professor in Immunology, University Of Southampton
14:10
Long-term maintenance of T cell memory by liposomes
Peter Andersen, Vice President Vaccine Research & Development , Statens Serum Institute
14:50
Peptides or DNA vaccines? Could Immunobody® be the answer?
Stephanie McArdle, Senior Research Scientist, Nottingham Trent University
15:30
Afternoon Tea
16:00
Gene Editing for Immunotherapy
Felipe Bedoya, Product Development and Correlative Sciences, University Of Pennsylvania
16:40
PANEL DISCUSSION
Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
16:40
PANEL DISCUSSION
Sebastian Kreiter, Head Immunotherapy Development Center, TRON Translational Oncology Mainz
16:40
PANEL DISCUSSION
Eric Leire, CEO, DanDrit Biotech
16:40
PANEL DISCUSSION
Peter Andersen, Vice President Vaccine Research & Development , Statens Serum Institute
16:40
PANEL DISCUSSION
John Maudsley, CEO, Cancer Vaccines Ltd

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report